` YPSN (Ypsomed Holding AG) vs Swiss Market Index Comparison - Alpha Spread

YPSN
vs
Swiss Market Index

Over the past 12 months, YPSN has outperformed Swiss Market Index, delivering a return of 14% compared to the Swiss Market Index's 4% growth.

Stocks Performance
YPSN vs Swiss Market Index

Loading
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
YPSN vs Swiss Market Index

Loading
YPSN
Swiss Market Index
Difference

Performance By Year
YPSN vs Swiss Market Index

Loading
YPSN
Swiss Market Index
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Ypsomed Holding AG vs Peers

Swiss Market Index
YPSN
7741
ALC
COLO B
ALGN
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Ypsomed Holding AG
Glance View

Market Cap
4.7B CHF
Industry
Health Care

Nestled amid the pioneering spirit of the Swiss medical technology landscape, Ypsomed Holding AG emerges as a quintessential player, carving a niche in the diabetes care and injection systems domains. The company’s journey begins in the Ypsomed headquarters in Burgdorf, Switzerland, where innovation meets precision engineering. Ypsomed's focus largely revolves around its development, production, and distribution of self-injection devices and solutions. This Swiss dynamo engages in crafting state-of-the-art insulin pumps, pen injectors, and smart add-on devices that empower users with diabetes to manage their conditions effectively. It combines clinical expertise with intuitive design, ensuring that their diverse clientele—from patients to medical professionals—receive products that blend seamlessly into everyday life. Not resting on insulin delivery alone, Ypsomed also establishes itself in the world of contract manufacturing, catering to global pharmaceutical and biotech companies with their platform technology and customized solutions. Economically vibrant, Ypsomed’s revenue streams are woven intricately from an array of channels. A significant proportion stems from direct sales of its proprietary diabetes care products under their acclaimed mylife™ brand. Here, it garners a loyal customer base through innovations like the YpsoPump® system, effectively capitalizing on the growing demand for user-friendly diabetes management tools. Additionally, Ypsomed capitalizes on partnerships with major healthcare multinationals by providing contract manufacturing services and licensing technologies, expanding its global footprint while tapping into broader markets. As a strategic player, the company continuously invests in research and development to refine its offerings and maintain a competitive edge in the burgeoning medical device market. Through this dynamic blend of cutting-edge technology and strategic alliances, Ypsomed illustrates a sophisticated business model that not only sustains its profitability but furthers its mission to improve the lives of those in need of reliable, advanced diabetes care solutions.

YPSN Intrinsic Value
313.25 CHF
Overvaluation 9%
Intrinsic Value
Price
Back to Top